jCyte Inc. Identifies Retinitis Pigmentosa Patients Most Likely to Respond in Planned Pivotal Study with jCell Therapy

jCyte’s presentation at ARVO 2021, demonstrated that retinitis pigmentosa patients treated with the 6 million cell dose of jCell therapy had significant gains in a broad range of visual function tests – BCVA, visual field (KVF), contrast sensitivity (CS), and low luminance mobility (LLMT) – all which measure important and different aspects of functional vision. jCyte also engaged the Cleveland Clinic to identify an anatomical biomarker for patient response to jCell therapy in retinitis pigmentosa, which will help guide the upcoming pivotal study.